A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
A phase 3 trial testing Domvanalimab in non-small-cell lung cancer, active and no longer recruiting.
Overview
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC is a phase 3 interventional study registered as NCT05211895, led by AstraZeneca with Arcus Biosciences, and active but no longer recruiting when checked on 2026-09-11. Official title: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy. Planned enrolment is 791 participants (actual). The study started in 2022-02-18 and primary completion is expected in 2026-08-10. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialZimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Shares Domvanalimab, Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
Shares AstraZeneca, Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Shares AstraZeneca, Non-small-cell lung cancer and the tag ctgov-ingest.
- TrialSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Shares AstraZeneca and the tag ctgov-ingest.
- TrialA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Shares AstraZeneca and the tag ctgov-ingest.
- TrialAssessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
Shares AstraZeneca and the tag ctgov-ingest.
- TrialAZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Shares AstraZeneca and the tag ctgov-ingest.
- TrialAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Shares AstraZeneca and the tag ctgov-ingest.